ILT-101: Clinical Trials

1 trial of ILT-101, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Not yet recruiting 1
Phase 21Not yet recruiting 1

Follow ILT-101: new trials by email Literature Review of ILT-101 trials Research Report on ILT-101

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.
FOXP3-T4 drug product, ILT-101 - The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3
Phase 1 / Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris52026-09-012026-07-13

Conditions studied

Autoimmune Diseases (1)  ·  Genetic Diseases, Inborn (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)

Countries

France (1)

NIH funding

2025 (1)